AVH Stock Overview
Operates as a regenerative medicine company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.97 |
| 52 Week High | US$5.62 |
| 52 Week Low | US$2.34 |
| Beta | 1.54 |
| 11 Month Change | 27.24% |
| 3 Month Change | 49.81% |
| 1 Year Change | 19.58% |
| 33 Year Change | -4.34% |
| 5 Year Change | -68.24% |
| Change since IPO | -92.65% |
Recent News & Updates
Shareholder Returns
| AVH | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0.3% | -3.6% | 1.5% |
| 1Y | 19.6% | 10.0% | 17.2% |
Return vs Industry: AVH exceeded the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: AVH exceeded the Australian Market which returned 17.2% over the past year.
Price Volatility
| AVH volatility | |
|---|---|
| AVH Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: AVH has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AVH's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 207 | Jim Corbett | www.avitamedical.com |
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time.
AVITA Medical, Inc. Fundamentals Summary
| AVH fundamental statistics | |
|---|---|
| Market cap | AU$526.45m |
| Earnings (TTM) | -AU$88.16m |
| Revenue (TTM) | AU$92.34m |
5.7x
P/S Ratio-6.0x
P/E RatioIs AVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVH income statement (TTM) | |
|---|---|
| Revenue | US$60.04m |
| Cost of Revenue | US$8.61m |
| Gross Profit | US$51.43m |
| Other Expenses | US$108.75m |
| Earnings | -US$57.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 85.66% |
| Net Profit Margin | -95.47% |
| Debt/Equity Ratio | 348.0% |
How did AVH perform over the long term?
See historical performance and comparison